RNA

RNA is currently in 'Deal Purgatory,' effectively pegged by the pending $12 billion acquisition by Novartis (announced Oct 2025) at ~$72/share. The 'Steady Climb' and 'Quiet Storm' signals are not indicating organic momentum, but rather the low-volatility compression typical of a merger arbitrage play approaching closure. The current price ($72.83) likely reflects the $72 cash consideration plus the residual implied value of the 'Atrium Therapeutics' spin-off (Record Date: Feb 12, 2026), creating a complex valuation bundle that is disconnected from the broader 'Caution' macro regime.